This webinar will focus on the specific challenges of creating assets for the manufacture of ATMP therapeutics whose success hinges upon how well this cutting-edge science translates into facility and process design.
Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform license.
